Impact of Brokerage Rating on Seattle Genetics, Inc.(SGEN)

Many Seattle Genetics, Inc.(SGEN) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Seattle Genetics was Downgraded by BofA/Merrill to Underperform on Feb 10, 2017. Seattle Genetics was Downgraded by Credit Suisse to Neutral on Dec 12, 2016. Company shares were Reiterated by RBC Capital Mkts on Dec 6, 2016 to Outperform, Raises Price Target to $ 72 from a previous price target of $62 .

Company has reported several Insider transactions to the SEC, on Feb 8, 2017, Clay B Siegall (President and CEO) sold 14,465 shares at 61.78 per share price.On Dec 15, 2016, Darren S Cline (EVP, Commercial) sold 10,000 shares at 63.80 per share price.On Dec 12, 2016, Eric Dobmeier (Chief Operating Officer) sold 12,500 shares at 65.95 per share price.

Seattle Genetics Last issued its quarterly earnings results on Feb 9, 2017. The company reported $-0.39 EPS for the quarter, missing the analyst consensus estimate by $ -0.07. Analyst had a consensus of $-0.32. The company had revenue of $105.30 million for the quarter, compared to analysts expectations of $106.60 million. The companys revenue was up 12.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.18 EPS.

Seattle Genetics, Inc. (NASDAQ:SGEN) has received a short term rating of strong sell from experts at Zacks with a rank of 5. The stock has been rated an average of 2.32 by 11 Brokerage Firm. 3 Wall Street Firms have rated the stock as a strong buys. 2 stock experts have also suggested a buy rating. 5 Brokerage Firms have advised hold. A sell rating was given by 1 analyst.

Seattle Genetics, Inc. (NASDAQ:SGEN): According to 11 Analysts, The short term target price has been estimated at $ 56.55.The target price could deviate by a maximum of $11.37 from the forecast price. In the near term, the target price could hit a high of $72 and a low of $ 42.

Seattle Genetics, Inc. (NASDAQ:SGEN) rose 2.09% or 1.29 points on Tuesday and made its way into the gainers of the day. After trading began at $61.34 the stock was seen hitting $62.9389 as a peak level and $60.945 as the lowest level. The stock ended up at $62.88. The daily volume was measured at 1,383,481 shares. The 52-week high of the share price is $75.36 and the 52-week low is $28.32. The company has a market cap of $8,901 million.

Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. The companys lead product, ADCETRIS? (brentuximab vedotin) is an ADC that, in collaboration with Takeda Pharmaceutical Company Limited, is commercially available for two indications in more than 45 countries, including the U.S., Canada, Japan and members of the European Union. Additionally, ADCETRIS is being evaluated broadly in more than 30 ongoing clinical trials. Seattle Genetics is also advancing a robust pipeline of clinical-stage ADC programs, including SGN-CD19A, SGN-CD33A, SGN-LIV1A, SGN-CD70A, ASG-22ME and ASG-15ME.

Seattle

For any feedback and suggestions contact author at Nancy.Wright@thefoundersdaily.com

Add Comment